NCT07423715

Brief Summary

This clinical study investigates whether electroacupuncture can improve thinking and memory in people with cognitive problems after a stroke (Post-Stroke Cognitive Impairment, or PSCI). Participants will be randomly assigned to one of two groups: one group will receive real electroacupuncture, while the other will receive a sham treatment . Both groups will also receive standard medical care.The main goal is to see if the real electroacupuncture leads to greater improvement in cognitive function tests over 6 months compared to the sham treatment. The study will also use brain scans (MRI) and other assessments to understand how the treatment might work.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
19mo left

Started Feb 2026

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Feb 2026Dec 2027

First Submitted

Initial submission to the registry

February 9, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

February 10, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 20, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

February 20, 2026

Status Verified

November 1, 2025

Enrollment Period

1.9 years

First QC Date

February 9, 2026

Last Update Submit

February 14, 2026

Conditions

Keywords

Post-Stroke Cognitive ImpairmentAcupoint RegulationBrain Electric Field Therapy

Outcome Measures

Primary Outcomes (4)

  • Change in Mini-Mental State Examination (MMSE) Score

    The Mini-Mental State Examination (MMSE) is a standardized 30-point questionnaire used to screen for cognitive impairment. Total scores range from 0 to 30, with higher scores indicating better cognitive function.

    baseline, 3 months and 6 months post-treatment.

  • Change in MoCA (Montreal Cognitive Assessment) Scale Score

    The Montreal Cognitive Assessment (MoCA) is a 30-point screening tool designed to detect mild cognitive impairment. Total scores range from 0 to 30, with higher scores indicating better cognitive function.

    baseline, 3 months and 6 months post-treatment.

  • Change in Clinical Dementia Rating (CDR) scale Score

    The Clinical Dementia Rating (CDR) is a clinician-rated scale that assesses the severity of dementia across six domains. The global CDR score ranges from 0 (no impairment) to 3 (severe dementia), with higher scores indicating greater severity of dementia.

    baseline, 3 months and 6 months post-treatment.

  • Change in NTB (Neuropsychological Test Battery) Score

    The Neuropsychological Test Battery (NTB) is a composite measure designed to assess cognitive function across multiple domains. It evaluates key areas including memory (e.g., verbal/visual recall), attention, executive function, and processing speed. A composite Z-score is derived by averaging the standardized scores of the individual cognitive tests. The composite score is interpreted such that higher scores indicate better overall cognitive performance.

    baseline, 3 months and 6 months post-treatment.

Secondary Outcomes (8)

  • Multimodal functional Near-Infrared Spectroscopy - Electroencephalogram (fNIRS-EEG) Assessment

    baseline, 3 months, and 6 month

  • Quality of Life as assessed by the Stroke-Specific Quality of Life Scale (SS-QOL)

    baseline, 3 months, and 6 months.

  • Depressive Symptoms as assessed by the Hamilton Depression Rating Scale (HRSD-24)

    baseline, 3 months, and 6 months

  • Traditional Chinese Medicine (TCM) Syndrome Score

    baseline, 3 months, and 6 months

  • MRI Examination

    baseline, 3 months, and 6 months

  • +3 more secondary outcomes

Study Arms (2)

True Electroacupuncture

EXPERIMENTAL
Procedure: True Electroacupuncture

Sham Electroacupuncture

SHAM COMPARATOR
Procedure: Sham Electroacupuncture

Interventions

The true electroacupuncture group will receive electroacupuncture treatment for 7 days, once a day, each session lasting approximately 30 minutes. Acupoints include main points (e.g., bilateral forehead lines, Tianzhu BL10, Fengchi GB20) and syndrome-based points. After needle insertion and manual stimulation for deqi, true EA (100 Hz dense wave, tolerable intensity) is applied the SDZ-IIB device, connecting MS2 and BL10 on each side.

True Electroacupuncture

The sham electroacupuncture group will receive electroacupuncture treatment for 7 days, once a day, each session lasting approximately 30 minutes.The same acupoints and needle insertion/manual stimulation are used. However, a modified SDZ-IIB device with severed leads (incapable of current output) is connected, simulating the appearance of true electroacupuncture without electrical stimulation. The treatment frequency and duration are identical to the electroacupuncture group.

Sham Electroacupuncture

Eligibility Criteria

Age35 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Meets diagnostic criteria for Vascular Cognitive Impairment (VCI) per the 2024 Chinese VCI guidelines.
  • Meets TCM diagnostic criteria per the 2024 Vascular Mild Cognitive Impairment guidelines.
  • Cognitive scores: MMSE 12-24 and MoCA \<24; NIHSS ≤8; AD-8 \<2.
  • Age 35-80 years.
  • Basic communication ability (Mandarin) and has a stable caregiver.
  • Provides written informed consent.

You may not qualify if:

  • Severe chronic systemic diseases (e.g., cardiac, hepatic, renal, hematologic) or unstable cardiovascular/cerebrovascular disease.
  • Local skin conditions (e.g., herpes, ulceration, keloid) contraindicating acupuncture.
  • Contraindications for repeated MRI (e.g., claustrophobia, post-aneurysm embolization).
  • Pre-existing cognitive impairment or other major uncontrolled neurological/psychiatric disorders.
  • Deemed unsuitable for the study by investigators.
  • Participation in another clinical trial within the past 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2026

First Posted

February 20, 2026

Study Start

February 10, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

February 20, 2026

Record last verified: 2025-11